Table 1.
Baseline Patient Demographics and Clinical Characteristics (Presence/Absence of Intra-Cardiac Thrombus).
| All Patients (n = 56) |
Thrombus Present (n = 21) |
Thrombus Absent (n = 35) |
p-value | |
|---|---|---|---|---|
| Age, years (median, IQR) | 63 (IQR: 51, 72) | 68 (IQR: 52, 82) | 62 (IQR: 51, 71) | 0.49 |
| Female gender, n, (%) | 14 (25%) | 6 (29%) | 8 (23%) | 0.63 |
| Comorbidities | ||||
| HTN, n (%) | 26 (46%) | 11 (52%) | 15 (43%) | 0.49 |
| Dyslipidemia, n (%) | 22 (39%) | 10 (48%) | 12 (34%) | 0.32 |
| Arrhythmia, n (%) | 7 (13%) | 4 (19%) | 3 (9%) | 0.41 |
| Prior VTE (DVT/PE), n (%) | 2 (4%) | 1 (5%) | 1 (3%) | 1.0 |
| Smoking, n (%) | 32 (57%) | 12 (57%) | 20 (57%) | 1.0 |
| Prior valvulopathy, n (%) | 7 (13%) | 1 (5%) | 6 (17%) | 0.18 |
| Charlson’s Comorbidity Index | ||||
| Age (<50y: 0, 50-59y: 1, 60-69y: 2, 70–79: 3, +80: 4), n (%) | <50 years: 11 (20%) 50–59 years: 12 (21%) 60–69 years: 13 (23%) 70–79 years: 13 (23%) 80 + years: 6 (11%) |
<50 years: 4 (19%) 50–59 years: 3 (14%) 60–69 years: 5 (24%) 70–79 years: 6 (29%) 80 + years: 3 (14%) |
<50 years: 7 (20%) 50–59 years: 9 (26%) 60–69 years: 8 (23%) 70–79 years: 7 (20%) 80 + years: 3 (9%) |
0.82 |
| MI, n (%) | 12 (21%) | 7 (33%) | 5 (14%) | 0.09 |
| CHF, n (%) | 4 (7%) | 2 (10%) | 2 (6%) | 0.63 |
| PVD, n (%) | 4 (7%) | 2 (10%) | 2 (6%) | 0.63 |
| CVA/TIA, n (%) | 5 (9%) | 3 (14%) | 2 (6%) | 0.28 |
| Dementia, n (%) | 4 (7%) | 1 (5%) | 3 (9%) | 0.59 |
| COPD, n (%) | 13 (23%) | 9 (43%) | 4 (11%) | 0.01 |
| Connective Tissue Disorder, n (%) | 4 (7%) | 2 (10%) | 2 (6%) | 0.63 |
| Peptic ulcer disease, n (%) | 7 (13%) | 1 (5%) | 6 (17%) | 0.24 |
| Liver disease (mild: 1, moderate-severe: 3), n (%) |
None: 51 (91%) Mild: 2 (4%) Mod-severe: 3 (5%) |
None: 19 (91%) Mild: 0 (0%) Mod-severe: 2 (10%) |
None: 32 (91%) Mild: 2 (6%) Mod-severe: 1 (3%) |
0.32 |
| Diabetes (uncomplicated: 1, end-organ damage: 2), n (%) | None: 43 (77%) Uncomplicated: 8 (14%) End-organ Damage: 5 (9%) |
None: 16 (76%) Uncomplicated: 2 (10%) End-organ Damage: 3 (14%) |
None: 27 (77%) Uncomplicated: 6 (17%) End-organ Damage: 2 (6%) |
0.45 |
| Hemiplegia, n (%) | 1 (2%) | 0 (0%) | 1 (3%) | 1.0 |
| CKD (mild: 1, mod-severe: 2), n (%) | None: 53 (95%) Mild: 2 (4%) Mod-severe: 1 (2%) |
None: 21 (94%) Mild: 0 (0%) Mod-severe: 0 (0%) |
None: 32 (91%) Mild: 2 (6%) Mod-severe: 1 (3%) |
0.39 |
| Solid tumour (localized: 2, metastatic: 6), n (%) | None: 50 (89%) Localized: 4 (7%) Metastatic: 2 (4%) |
None: 19 (91%) Localized: 2 (10%) Metastatic: 0 (0%) |
None: 31 (89%) Localized: 2 (6%) Metastatic: 2 (6%) |
0.48 |
| Leukemia, n (%) | 1 (2%) | 1 (5%) | 0 (0%) | 0.38 |
| Lymphoma, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.0 |
| AIDS, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.0 |
| Charlson’s Comorbidity Index (total score), (median, IQR) | 4 (IQR: 2, 6) |
4 (IQR: 2, 6) |
3 (IQR: 1, 6) |
0.69 |
AIDS = acquired immunodeficiency syndrome, CHF = congestive heart failure, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, CVA = cerebral vascular accident, DVT = deep venous thrombosis, HTN = hypertension, IQR = interquartile range, MI = myocardial infarction, PE = pulmonary embolism, PEA = pulseless electrical activity, PVD = peripheral vascular disease, SD = standard deviation, TIA = transient ischemic attack, VF = ventricular fibrillation, VT = ventricular tachycardia, VTE = venous thromboembolism.